ICUI · Icu Medical Inc/De - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.23B | $2.38B | $2.26B | $2.28B | $1.32B | $1.27B |
| Cost of Revenue | $1.41B | $1.56B | $1.52B | $1.58B | $824.82M | $809.51M |
| Gross Profit | $822.04M | $824.78M | $739.87M | $697.76M | $491.49M | $461.50M |
| R&D | $87.50M | $88.61M | $85.34M | $92.98M | $47.50M | $42.95M |
| SG&A | $625.21M | $638.76M | $606.69M | $608.35M | $302.58M | $283.95M |
| Total Operating Expenses | $779.21M | $781.82M | $717.05M | $740.66M | $368.25M | $363.33M |
| D&A | $200.74M | $219.51M | $228.77M | $235.15M | $89.70M | $85.63M |
| Operating Income | $42.83M | $42.96M | $22.82M | ($42.90M) | $123.25M | $98.16M |
| Interest Expense | $93.34M | $106.54M | $102.73M | $70.81M | $858.0K | $1.75M |
| Income Tax | $2.44M | $51.68M | ($48.64M) | ($40.12M) | $20.05M | $10.62M |
| Net Income | $732.0K | ($117.69M) | ($29.66M) | ($74.29M) | $103.14M | $86.87M |
| EPS - Basic | $0.03 | ($4.83) | ($1.23) | ($3.11) | $4.86 | $4.16 |
| EPS - Diluted | $0.03 | ($4.83) | ($1.23) | ($3.11) | $4.74 | $4.02 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $307.96M | $308.57M | $254.22M | $208.78M | $552.83M | $396.10M |
| Accounts Receivable | $180.51M | $182.83M | $161.57M | $221.72M | $105.89M | $124.09M |
| Inventory | $615.86M | $584.68M | $709.36M | $696.01M | $290.24M | $314.93M |
| Accounts Payable | $154.37M | $148.02M | $150.03M | $215.90M | $81.13M | $71.86M |
| Current Assets | $1.19B | $1.44B | $1.22B | $1.24B | $1.03B | $920.78M |
| Total Assets | $4.05B | $4.20B | $4.38B | $4.52B | $1.88B | $1.76B |
| Current Liabilities | $498.86M | $556.18M | $481.84M | $494.56M | $200.78M | $195.49M |
| Long-term Debt | $1.27B | $1.53B | $1.58B | $1.62B | - | - |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $2.12B | $1.97B | $2.12B | $2.09B | $1.62B | $1.50B |
| Retained Earnings | $690.89M | $690.16M | $807.85M | $837.50M | $911.79M | $808.65M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $179.85M | $204.03M | $166.20M | ($62.13M) | $267.54M | $222.75M |
| Investing Cash Flow | $122.23M | ($88.96M) | ($87.95M) | ($1.91B) | ($90.69M) | ($98.14M) |
| Financing Cash Flow | ($311.52M) | ($55.80M) | ($35.98M) | $1.64B | ($16.87M) | ($40.0K) |
| CapEx | $88.04M | $79.37M | $83.89M | $90.31M | $68.54M | $92.00M |
| Free Cash Flow | $91.80M | $124.66M | $82.31M | ($152.44M) | $199.00M | $130.75M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 36.8% | 34.6% | 32.8% | 30.6% | 37.3% | 36.3% |
| Operating margin | 1.9% | 1.8% | 1.0% | -1.9% | 9.4% | 7.7% |
| EBITDA margin | 10.9% | 11.0% | 11.1% | 8.4% | 16.2% | 14.5% |
| Net margin | 0.0% | -4.9% | -1.3% | -3.3% | 7.8% | 6.8% |
| Free cash flow margin | 4.1% | 5.2% | 3.6% | -6.7% | 15.1% | 10.3% |
| FCF / Net income | 125.42 | -1.06 | -2.78 | 2.05 | 1.93 | 1.51 |
| R&D / Revenue | 3.9% | 3.7% | 3.8% | 4.1% | 3.6% | 3.4% |
| SG&A / Revenue | 28.0% | 26.8% | 26.9% | 26.7% | 23.0% | 22.3% |
| Effective tax rate | 76.9% | - | - | - | 16.3% | 10.9% |
| Return on assets | 0.0% | -2.8% | -0.7% | -1.6% | 5.5% | 4.9% |
| Return on equity | 0.0% | -6.0% | -1.4% | -3.6% | 6.4% | 5.8% |
| Return on invested capital | 0.6% | 1.0% | 0.5% | -0.9% | - | - |
| Liquidity | ||||||
| Current ratio | 2.39 | 2.59 | 2.53 | 2.50 | 5.13 | 4.71 |
| Quick ratio | 1.15 | 1.54 | 1.06 | 1.09 | 3.68 | 3.10 |
| Cash ratio | 0.62 | 0.55 | 0.53 | 0.42 | 2.75 | 2.03 |
| Leverage | ||||||
| Debt / Equity | 0.60 | 0.78 | 0.74 | 0.78 | - | - |
| Debt / Assets | 0.31 | 0.36 | 0.36 | 0.36 | - | - |
| Debt / EBITDA | 5.20 | 5.84 | 6.27 | 8.45 | - | - |
| Interest coverage | 0.5x | 0.4x | 0.2x | -0.6x | 143.6x | 56.0x |
| Equity multiplier | 1.91 | 2.14 | 2.06 | 2.16 | 1.16 | 1.17 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.55 | 0.57 | 0.52 | 0.50 | 0.70 | 0.72 |
| Inventory turnover | 2.29 | 2.66 | 2.14 | 2.27 | 2.84 | 2.57 |
| Days sales outstanding | 30d | 28d | 26d | 35d | 29d | 36d |
| Days inventory outstanding | 160d | 137d | 170d | 161d | 128d | 142d |
| Days payable outstanding | 40d | 35d | 36d | 50d | 36d | 32d |
| Cash conversion cycle | 149d | 130d | 160d | 146d | 122d | 145d |
| Valuation | ||||||
| P / E | 4755.7x | - | - | - | 50.1x | 53.4x |
| P / B | 1.7x | 1.9x | 1.1x | 1.8x | 3.2x | 3.1x |
| P / S | 1.6x | 1.6x | 1.1x | 1.6x | 3.9x | 3.6x |
| EV / EBITDA | 18.5x | 19.1x | 14.8x | 26.9x | 21.7x | 23.0x |
| Growth | ||||||
| Revenue growth (YoY) | -6.3% | 5.4% | -0.9% | 73.2% | 3.6% | 0.4% |
| Revenue CAGR (3y) | -0.7% | 21.9% | 21.1% | 21.7% | -2.0% | -0.6% |
| Revenue CAGR (5y) | 11.9% | 13.5% | 10.0% | 12.0% | 28.3% | 30.0% |
| Gross profit growth (YoY) | -0.3% | 11.5% | 6.0% | 42.0% | 6.5% | -2.2% |
| Operating income growth (YoY) | -0.3% | 88.2% | - | - | 25.6% | -8.6% |
| Net income growth (YoY) | - | -296.9% | 60.1% | - | 18.7% | -14.0% |
| EPS growth (YoY) | - | -292.7% | 60.5% | - | 17.9% | -14.3% |
| EPS CAGR (3y) | - | - | - | - | 52.7% | 6.9% |
| EPS CAGR (5y) | -62.5% | - | - | - | 5.3% | 8.0% |
| FCF growth (YoY) | -26.4% | 51.5% | - | - | 52.2% | 2738.6% |
| FCF CAGR (5y) | -6.8% | 93.4% | 4.0% | - | 24.5% | 25.6% |
| Book value growth (YoY) | 8.1% | -7.4% | 1.6% | 29.3% | 7.6% | 9.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$2.23B totalInfusion Consumables$1.11B · 49.7%
Infusion Systems$684.21M · 30.7%
Vital Care$437.92M · 19.6%
Geographic
$2.23B totalUS$1.36B · 60.8%
EMEA$411.68M · 18.5%
APACDomain$232.90M · 10.4%
Otherforeigncountries$230.56M · 10.3%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing ICU MEDICAL INC/DE against the 5 most active filers in the same SIC group.